LRFN4 and breast carcinoma: Previous reports on lung, colon, and breast cancers have demonstrated that LRFN4’s ability to enhance cell proliferation, invasion, and chemotherapy resistance, suggesting its involvement in multiple oncogenic pathways (43, 44).